Last reviewed · How we verify
CS6253 Solution for Injection
At a glance
| Generic name | CS6253 Solution for Injection |
|---|---|
| Sponsor | Artery Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of CS6253 in Healthy Volunteers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CS6253 Solution for Injection CI brief — competitive landscape report
- CS6253 Solution for Injection updates RSS · CI watch RSS
- Artery Therapeutics, Inc. portfolio CI